CVR: 40279865
Secondary names: Ciana Therapeutics ApS
DKK -7,545,558
Gross profit
Net result: DKK -89,139,846
Novo Holdings A/S, Visus Holding ApS
3 more
CVR · view ownership and management
Owner registered: Novo Holdings A/S
CVR · 17/07/2024
View the full event history
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Ulrik Mouritzen. The company's owners include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S. In 2025, the company reported a gross profit of DKK -7,545,558 and a net result of DKK -89,139,846 compared with DKK -70,150,057 the year before. Equity in the 2025 report amounted to DKK -40,637,790.
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/04/2024 – 31/03/2025 | -7.5 mio. | -89.1 mio. | 57 mio. | -40.6 mio. | 3 | |
| 202401/04/2023 – 31/03/2024 | -7.8 mio. | -70.2 mio. | 60.7 mio. | 48.5 mio. | 2 | |
| 202301/04/2022 – 31/03/2023 | -2.9 mio. | -14.6 mio. | 24.8 mio. | 14.5 mio. | 1 | |
| 202201/04/2021 – 31/03/2022 | -674 t. | -780 t. | 18.7 mio. | -752 t. | 1 | |
| 202101/04/2020 – 31/03/2021 | -68 t. | -290 t. | 14.2 mio. | 28 t. | 1 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorBreye Therapeutics ApS was founded on 13 February 2019.
Breye Therapeutics ApS is registered under the industry Fremstilling af farmaceutiske præparater (industry code 212000).
The owners of Breye Therapeutics ApS include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S.
In 2025, Breye Therapeutics ApS reported a gross profit of DKK -7,545,558.
The management of Breye Therapeutics ApS consists of Ulrik Mouritzen.
Breye Therapeutics ApS is located at Agern Alle 24, 2970 Hørsholm.
Claim this page to add your logo and social links. Free to get started.
Breye Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -7,545,558, and the net result was DKK -89,139,846.
Breye Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -7,812,131, and the net result was DKK -70,150,057.
As of July 17, 2024, Novo Holdings A/S is registered as an owner of Breye Therapeutics ApS with an ownership share of 33%.
As of July 17, 2024, Visus Holding ApS is registered as an owner of Breye Therapeutics ApS with an ownership share of 10%.
As of July 17, 2024, is registered as an owner of Breye Therapeutics ApS with an ownership share of 5%.
Breye Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -2,882,747, and the net result was DKK -14,574,884.
As of June 6, 2023, Chiara Rossana Maria Liberati has joined the board of directors of Breye Therapeutics ApS.
As of June 6, 2023, BII Holdings A/S is registered as an owner of Breye Therapeutics ApS with an ownership share of 5%.
As of June 6, 2023, is registered as an owner of Breye Therapeutics ApS with an ownership share of 20%.
As of December 5, 2022, Gabriela Burian has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, EY Godkendt Revisionspartnerselskab has been appointed auditor of Breye Therapeutics ApS.
As of November 4, 2022, EMIT P/S has stepped down as auditor of Breye Therapeutics ApS.
As of November 4, 2022, Jørgen Søberg Petersen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Ulrik Mouritzen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Jimmy Arnold V Van Heusden has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Carl Johan Kördel has joined the board of directors of Breye Therapeutics ApS.
Breye Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -673,849, and the net result was DKK -780,005.
Breye Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -67,528, and the net result was DKK -289,668.
As of October 29, 2020, EMIT P/S has been appointed auditor of Breye Therapeutics ApS.
Breye Therapeutics ApS has published its interim report for the period February 13, 2019 – March 31, 2020.
As of February 13, 2019, Ulrik Mouritzen is registered as adm. dir. of Breye Therapeutics ApS.
Breye Therapeutics ApS was founded on February 13, 2019.
Companies in the same industry and area
CVR 29526346
CVR 37728403
CVR 34623562
CVR 38445928
CVR 63717916
